Protective role of cortistatin in pulmonary inflammation and fibrosis.
Margarita BarrigaRaquel BenitezViviane Ferraz-de-PaulaMarina Garcia-FrutosMarta CaroGema RobledoFrancisco O'ValleJenny Campos-SalinasMario DelgadoPublished in: British journal of pharmacology (2021)
We identified cortistatin as an endogenous inhibitor of pulmonary inflammation and fibrosis. Deficiency in cortistatin could be a marker of poor prognosis in inflammatory/fibrotic pulmonary disorders. Cortistatin-based therapies could emerge as attractive candidates to treat severe ALI/ARDS, including SARS-CoV-2-associated ARDS.